Prioritized antimicrobial drugs would gain an extra year of market exclusivity under new bipartisan legislation introduced in the House by Reps. John Shimkus (R-Ind.) and Tony Cardenas (D-Calif.) to encourage the development of antimicrobials.

The legislation, named the Re-Valuing Anti-Microbial Products Act of 2018 (REVAMP Act), would organize an expert committee of government officials and doctors to create a list of critical-need antimicrobial products.

The bill’s proposed exclusivity would be transferable to other drugs and able to be “parceled for periods less than 12 months,” although cosmetics, biologics and drugs seeking approval via the supplemental approval pathway would not qualify for the legislation’s extended exclusivity.